Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8CW9E
|
|||
| Drug Name |
Beremagene geperpavec
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Epidermolysis bullosa [ICD-11: EC3Z] | Phase 3 | [1] | |
| Company |
Krystal Biotech Pittsburgh, PA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Collagen VII (COL7A1) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04491604) A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously "KB103") for the Treatment of Dystrophic Epidermolysis Bullosa (DEB). U.S.National Institutes of Health. | |||
| REF 2 | Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med. 2022 Dec 15;387(24):2211-2219. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.